Analysis of a tumor sample collected from a patient with BRCA–wild-type/LOH-low genotype who had a complete response to rucaparib showed amplification of cyclin E1 (CCNE1), which is able to suppress BRCA1 expression [97]. This evidence concerns the gene CCNE1 and neoplasm.